Compare HCA Health Inc (HCA) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HCA Health Inc vs TG Therapeutics Inc — how do they compare? HCA Health Inc trades at $451.09 (market cap $96.35B), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: HCA Health Inc is far larger — about 11.8× TG Therapeutics Inc's market cap, and HCA Health Inc pays a 0.7% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold HCA Health Inc for 76 Days and TG Therapeutics Inc for 16 Days on average.
| HCA | TGTX | |
|---|---|---|
Market Cap | $96.35B | $8.16B |
Volume | 1,079,453 | 1,735,121 |
Sector | Health | Health |
52-Week High | $545.13 | $59.06 |
52-Week Low | $361.32 | $26.94 |
Typical Hold Time | 76 Days | 16 Days |
Enterprise Value | $146.88B | $8.37B |
Dividend Yield | 0.7% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HCA Healthcare trades at $445.01, up 1.33% today, with a bullish technical signal and strong earnings beats in recent quarters. Revenue grew to $75.60 billion in 2025, with net income of $6.78 billion, while valuation metrics like a P/E of 14.92 appear reasonable. The company announced a dividend of $0.78 and completed the acquisition of The College of Health Care Professions, signaling growth initiatives.
The outlook is positive, supported by analyst consensus with a $461.12 price target and 63% buy ratings, though risks include ongoing legal investigations and high debt levels. Earnings growth and operational efficiency remain key drivers for potential upside, but investors should monitor regulatory and competitive pressures.
TG Therapeutics (TGTX) trades at $53.34, up 0.74% today, but faces bearish technical signals despite strong profitability metrics like a 55.22% net income margin. Recent earnings misses and a shareholder investigation create headwinds, though revenue growth and a high analyst buy consensus of 84.62% suggest underlying strength. The stock's current price is near key support at $52, with resistance at $54.
The outlook is mixed: robust revenue growth and institutional buying support upside toward the $80.50 consensus target, but earnings misses and legal risks pose challenges. Investors should weigh the company's MS therapy momentum against execution and regulatory uncertainties for balanced risk-reward assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About HCA Health Inc
HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the U.S. As of December 2021, the firm owned and operated 182 hospitals, 125 freestanding outpatient surgery centers, and a broad network of physician offices, urgent care clinics, and freestanding emergency rooms across nearly 20 states and a small foothold in England.
Read more on HCA →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
